Form 4: Charles River Laboratories Director George Massaro Sells Shares Under 10b5-1 Trading Plan

Director George Massaro of Charles River Laboratories sold a portion of his common stock holdings on May 14, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 14, 2025, George Massaro, a director at Charles River Laboratories International, Inc., sold shares of common stock.
• The sales were executed in multiple transactions at varying prices.
• The weighted average sale prices for these transactions ranged from $139.95 to $145.54.
• A total of 140 shares were sold.
• These sales were conducted under a pre-existing 10b5-1 trading plan adopted on August 19, 2024.
• Following these transactions, Massaro directly owns 5,715 shares of Charles River Laboratories common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged trading plan, which is a common practice.

Industry Context

Sales by company insiders are routinely monitored by investors. Sales under a 10b5-1 plan are less likely to be interpreted as a negative signal, as these plans are pre-arranged and often used for diversification or liquidity purposes.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the existence of a 10b5-1 trading plan mitigates concerns about insider sentiment.

Key Dates

Keywords

Form 4, Charles River Laboratories, CRL, George Massaro, Stock Sale, Director, 10b5-1 Trading Plan, Beneficial Ownership, Securities